Krystal Biotech Inc. (KRYS) exhibits 41.0% gross margins and 16.5% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 53.4x enterprise multiple and 6.6% implied options volatility.
Sustained 41.0% gross profitability converts into 41.5% operating margin and 16.5% ROIC, outpacing sector cost of capital.
ROIC: 16.5% // GM: 41.0%YoY revenue trajectory of +33.9% paired with 1.97% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +33.9% // FCF YLD: 1.97%Altman Z-Score of 26.00 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 8/9Trading at 46.9x trailing P/E (39.4x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 46.9x // EV/EBITDA: 53.4xOptions market prices a ±6.6% implied move with a 0.82 put/call ratio around $318.00 max pain.
IMPL MOVE: ±6.6% // P/C: 0.82Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 52.6% net margins.
NET MARGIN: 52.6% // D/E: 0.04x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for KRYS & activate live FRED threshold breach alerts.